Development and Validation of the Quantification of GML-1 Compound ( N -benzyl- N -methyl-1-phenylpyrrolo[1,2- A ] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

A. A. Novitskiy; P. O. Bochkov; A. A. Litvin; V. P. Zherdev; E. V. Blynskaya

doi:10.3103/S0027131418010042

Development and Validation of the Quantification of GML-1 Compound (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-A] pyrazine- 3-carbamide) in the Blood Plasma of Rats by HPLC–MS

Авторлар: Novitskiy A.A.¹, Bochkov P.O.¹, Litvin A.A.¹, Zherdev V.P.¹, Blynskaya E.V.¹
Мекемелер:
1. Zakusov Institute of Pharmacology
Шығарылым: Том 72, № 6 (2017)
Беттер: 322-324
Бөлім: Article
URL: https://journals.rcsi.science/0027-1314/article/view/163557
DOI: https://doi.org/10.3103/S0027131418010042
ID: 163557

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Қосымша файлдар
Статистика

Аннотация

The technique of quantitative determination of a new compound, possessing anxiolytic activity, GML-1 in the blood plasma of rats is developed and validated. The analysis is performed by HPLC–MS. The method is linear in the range of 50–1000 ng/mL. 83.63% of GML-1 was recovered. The detection limit was 25 ng/mL.